ConductScience.org, home

Comparison · NCT01949662-cf2c8696

Intervention Group (Lorazepam & Haloperidol) vs Control Group (Placebo & Haloperidol): Number of Participants With Richmond Agitation-Sedation Scale Score >=1 Within 8 hr

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intervention Group (Lorazepam & Haloperidol) vs Control Group (Placebo & Haloperidol): Number of Participants With Richmond Agitation-Sedation Scale Score >=1 Within 8 hr. Trial comparisons, record NCT01949662-cf2c8696. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01949662-cf2c8696

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2760.1470.457wilson
Risk in group 20.7590.5790.878wilson
Risk difference, group 1 minus group 2-0.483-0.658-0.227newcombe hybrid score
Risk ratio, group 1 over group 20.3640.1950.679log
Odds ratio, group 1 over group 20.1210.03730.393log
Number needed to treat, for one fewer participant with the outcome on Intervention Group (Lorazepam & Haloperidol) than on Control Group (Placebo & Haloperidol)2.071.524.4from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Intervention Group (Lorazepam & Haloperidol)Received single dose of Lorazepam (3 mg IV, once) and Haloperidol (2mg IV, once)829OG000
Group 2Control Group (Placebo & Haloperidol)Received single dose of Haloperidol (2mg IV, once)2229OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Richmond Agitation-Sedation Scale Score >=1 Within 8 hr
Description
Number of participants with Richmond Agitation-Sedation Scale score \>=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.
Time frame
Baseline to 8 hours
Population
Intent to treat 58 participants, a total of 29 from each arm

Source ClinicalTrials.gov

Trial

Title
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
NCT number
NCT01949662
Phases
PHASE2
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Lead sponsor
M.D. Anderson Cancer Center
Results first posted
2020-10-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01949662-cf2c8696